Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel.

Oral Presentation:

Pompe Disease:

Abstract Title: Switching treatment from alglucosidase alfa to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease

• Presenter: Priya Kishnani, MD, MBBS, Duke University Medical Center, Durham, NC, U.S.A.
• Session: Clinical Studies & Outcomes I
• Date and time: Wednesday, August 30, 8:45-9:00 a.m. I.D.T.
• Location: Oren 2

Poster Sessions:

Fabry Disease:

Abstract Title: Multiorgan involvement in females with Fabry disease: results from two phase III trials and the followME registry (Poster #B169)

• Presenter: Peter Nordbeck, MD, University Hospital Würzburg, Würzburg, Germany
• Location: Exhibit Hall

Abstract Title: Exploring the Experiences of Females Living with Fabry Disease in Canada (Poster #B12)

• Presenter: Julia Alton, Executive Director, Canadian Fabry Association, Ontario, Canada
• Location: Exhibit Hall

Pompe Disease:

Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa (Poster #B167)

• Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
• Location: Exhibit Hall

Abstract Title: Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials (Poster #B20)

• Presenter: Ozlem Goker-Alpan, MD, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, U.S.A
• Location: Exhibit Hall

Abstract Title: Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #B168)

• Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
• Location: Exhibit Hall

For more information on the SSIEM Annual Symposium 2023, please visit ssiem2023.org.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G